PET Imaging of Response and Resistance to Cancer Therapy

DOI: 10.1007/978-1-59745-035-5_5

ABSTRACT As cancer treatment moves towards more targeted therapy, there is an increasing need for tools to guide therapy selection
and to evaluate response. Biochemical and molecular imaging can complement existing in vitro assay methods and is likely to
play a key role in early drug testing and development, as well as future clinical practice. Imaging is ideally suited to assessing
the spatial and temporal heterogeneity of cancer and to measure in vivo drug effects. This chapter highlights imaging approaches
to guide cancer therapy, focusing on positron emission tomography and on those approaches that have undergone preliminary
testing in patients. Examples showing how positron emission tomography imaging can be used to (1) assess the therapeutic target,
(2) identify resistance factors, and (3) measure early response are described.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, resistance being either preexisting (intrinsic resistance) or induced by the drugs (acquired resistance). At present, resistance is usually diagnosed during treatment after a long period of drug administration.In the present paper, methods for a rapid assessment of drug resistance are described. Three main classes of test procedures can be found in the literature, i.e. fresh tumor cell culture tests, cancer biomarker tests and positron emission tomography (PET) tests. The methods are based on the evaluation of molecular processes, i.e. metabolic activities of cancer cells. Drug resistance can be diagnosed before treatment in-vitro with fresh tumor cell culture tests, and after a short time of treatment in-vivo with PET tests. Cancer biomarker tests, for which great potential has been predicted, are largely still in the development stage. Individual resistance surveillance with tests delivering rapid results signifies progress in cancer therapy management, by providing the possibility to avoid drug therapies that are ineffective and only harmful.
    International journal of medical sciences 01/2011; 8(3):245-53. · 2.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biochemical and molecular imaging of cancer using positron emission tomography (PET) plays an increasing role in the care of cancer patients. Most clinical work to date uses the glucose analogue [(18)F]fluorodeoxyglucose (FDG) to detect accelerated and aberrant glycolysis present in most tumors. Although clinical FDG PET has been used largely to detect and localize cancer, more detailed studies have yielded biological insights and showed the utility of FDG as a prognostic marker and as a tool for therapeutic response evaluation. As cancer therapy becomes more targeted and individualized, it is likely that PET radiopharmaceuticals other than FDG, aimed at more specific aspects of cancer biology, will also play a role in guiding cancer therapy. Clinical trials designed to test and validate new PET agents will need to incorporate rigorous quantitative image analysis and adapt to the evolving use of imaging as a biomarker and will need to incorporate cancer outcomes, such as survival into study design.
    Clinical Cancer Research 07/2007; 13(12):3460-9. · 7.84 Impact Factor